| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Surgical treatment is the first line treatment for the patients with early stage renal cell cancer (RCC). But, it is well known that about 10% of these patients who were performed appropriate treatments will become to recur of RCC and also late recurrence was often found in these patients more than 10 years after the surgery. Although these phenomena are thought to be closely associated with the immunological statement of the hosts, what type of immune cells play a role of immunological surveillance against RCC are still unclear. In this study, we showed that peripheral blood gamma-delta T cells might inhibit the recurrence of RCC for the patients of early stage RCC after the surgery. Our results will give a cue for an appropriate clinical follow-up schedule for these patients whose peripheral blood gamma delta T cells were low number and help to develop of a new immunotherapy for recurrence prevention.
|
